208794orig1s000 · from: hitesh shroff, ph.d. application technical lead, branch v division of new...
TRANSCRIPT
![Page 1: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/1.jpg)
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
208794Orig1s000
CHEMISTRY REVIEW(S)
![Page 2: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/2.jpg)
Memorandum DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH
Date: January 12, 2017 From: Hitesh Shroff, Ph.D.
Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products
Through: Moo-Jhong Rhee, Ph.D.
Chief, Branch V Division of New Drug Products II Office of New Drug Products
To: CMC Review #1 of NDA 208794
Subject: Final Recommendation for NDA 208794 At the time when the CMC Review #1 was completed on November 28, 2016, it had noted the following pending issues:
• The label/labeling issues were not resolved. Because of these deficiencies, the NDA was not recommended for approval from the OPQ perspective.
On December 7, 2016, the applicant submitted revised labeling. The CMC sections of the labeling were reviewed by Dr. Zhengfang Ge and found acceptable (Attachment -1) from CMC perspective.
Recommendation: This NDA is now recommended for Approval from the OPQ perspective.
Application Technical Lead’s Assessment and Signature
The NDA is recommended for Approval from quality perspective.
Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II January 12, 2017
![Page 3: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/3.jpg)
![Page 4: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/4.jpg)
![Page 5: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/5.jpg)
![Page 6: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/6.jpg)
![Page 7: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/7.jpg)
![Page 8: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/8.jpg)
![Page 9: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/9.jpg)
![Page 10: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/10.jpg)
![Page 11: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/11.jpg)
![Page 12: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/12.jpg)
![Page 13: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/13.jpg)
![Page 14: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/14.jpg)
![Page 15: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/15.jpg)
![Page 16: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/16.jpg)
MichaelFurness
Digitally signed by Michael Furness
Date: 10/24/2016 01:57 34PM
GUID: 502e8c7600003dd8331cf6eebf43697a
Comments: EA secondary complete
RaananBloom
Digitally signed by Raanan Bloom
Date: 10/26/2016 01:37 08PM
GUID: 508da72a0002a6d1071f3297897e4f1f
![Page 17: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/17.jpg)
![Page 18: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/18.jpg)
![Page 19: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/19.jpg)
![Page 20: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/20.jpg)
![Page 21: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/21.jpg)
![Page 22: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/22.jpg)
![Page 23: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/23.jpg)
![Page 24: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/24.jpg)
![Page 25: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/25.jpg)
![Page 26: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/26.jpg)
![Page 27: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/27.jpg)
![Page 28: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/28.jpg)
![Page 29: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/29.jpg)
Moo JhongRhee
Digitally signed by Moo Jhong Rhee
Date: 8/31/2016 01:46:37PM
GUID: 502d0913000029f9798ca689a802fa55
ZhengfangGe
Digitally signed by Zhengfang Ge
Date: 8/31/2016 12:46:51PM
GUID: 508da7210002a030e76df4f60ccd142a
43 Page(s) have been Withheld in Full as b4 (CCI/TS) immediately following this page
![Page 30: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/30.jpg)
![Page 31: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/31.jpg)
![Page 32: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/32.jpg)
![Page 33: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/33.jpg)
![Page 34: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/34.jpg)
![Page 35: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/35.jpg)
![Page 36: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/36.jpg)
![Page 37: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/37.jpg)
![Page 38: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/38.jpg)
![Page 39: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/39.jpg)
![Page 40: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/40.jpg)
![Page 41: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/41.jpg)
![Page 42: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/42.jpg)
![Page 43: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/43.jpg)
Tien MienChen
Digitally signed by Tien Mien Chen
Date: 10/05/2016 04:10 06PM
GUID: 508da7240002a26723d38018ce005126
HansongChen
Digitally signed by Hansong Chen
Date: 10/05/2016 03:40:10PM
GUID: 525d7d660003845a197a2e1682433d0d
![Page 44: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/44.jpg)
ATTACHMENT I: Method Validation Summary
![Page 45: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/45.jpg)
![Page 46: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/46.jpg)
![Page 47: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/47.jpg)
![Page 48: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/48.jpg)
![Page 49: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/49.jpg)
ATTACHMENT III: List of Deficiencies for Complete Response
1. Labeling Deficiencies 1. Regarding Highlighted section
The established name should be changed to (telotristat ethy) tablets per CDER Salt
Nomenclature policy
The Dosage Forms and Strengths should be displayed as “Tablets: 250 mg telotristat ethy”
2. Regarding # 3: Dosage Forms and Strengths
This section should be changed to “Tablets: 250mg telotristat ethtyl is a white to ….”
3. Regarding the #11Description section
The 1st sentence should be changed to “Xermelo (telotristat ethyl) tablets contain telotristat ethyl as telotristat etiprate, a tryptophan hydroxylase inhibitor”
“Each Xermelo tablet contains 250 mg of telotristat ethyl (free base) which is equivalent to 328 mg telotristat etiprate” should be added.
should be removed from the active ingredients.
4. Regarding #16: How Supplied/Storage and Handling In order to avoid potential medical errors using
drug product samples have been requested through DMEPA. A final decision for a better description will be decided after receiving the drug product.
(b) (4)
(b) (4)
![Page 50: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/50.jpg)
![Page 51: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/51.jpg)
![Page 52: 208794Orig1s000 · From: Hitesh Shroff, Ph.D. Application Technical Lead, Branch V Division of New Drug Products II Office of New Drug Products Through: Moo-Jhong Rhee, Ph.D. Chief,](https://reader033.vdocuments.net/reader033/viewer/2022050519/5fa2c1f8c0fe385ae97f85c5/html5/thumbnails/52.jpg)
HiteshShroff
Digitally signed by Hitesh Shroff
Date: 11/28/2016 10:32:40AM
GUID: 502d1ab500002afd219fd67e3b9c99c8